Tags : $7.2M


Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology

Shots: Puma to receive upfront, milestones up to $7.2M and royalties on sales in Canada. Knight to get exclusive commercialization rights for Nerlynx and will also be responsible for its regulatory approvals in Canada In July, 2018 Puma has filled Nerlyn’s NDA to Health Canada for the treatment of early stage HER2-overexpressed/amplified breast cancer following […]Read More